Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Phase 1 Study of NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

NCT04659629 is registered in ClinicalTrials.gov with Neurogene Inc. as lead sponsor.

NCT NCT04659629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04659629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Phase 1 Study of NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Lead sponsor
Neurogene Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 26, 2021
Completion date
August 15, 2024
Enrollment
59 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, solid tumor